Addressing a Global Health Crisis
An estimated 55 million people globally are living with dementia and Alzheimer's disease. These neurodegenerative conditions progressively impair cognitive functions, resulting in:
The burden of these diseases extends beyond the afflicted, deeply affecting families and caregivers. With no established cure, hope for patients and their loved ones has been limited—until now.
TauRx, founded by Professor Claude Wischik and his team, has led pioneering research into the role of tau protein in dementia for over three decades. Their work has unlocked a groundbreaking approach to treating Alzheimer’s disease.
In healthy brains, tau proteins stabilize microtubules, which are essential for nutrient transport within neurons. In Alzheimer's patients, these tau proteins malfunction, leading to the formation of tangles that disrupt neuronal function and cause cell death. Tau buildup is a hallmark of Alzheimer's and a key factor in disease progression.
TauRx's investigational drug, LMTX®, targets tau pathology to halt or even reverse the progression of neurodegenerative diseases. Phase III clinical trials demonstrated promising outcomes:
This therapy represents a potential paradigm shift, addressing the root cause of Alzheimer’s rather than merely managing symptoms. With global Alzheimer's cases projected to triple by 2050, LMTX® could revolutionize treatment.
The Alzheimer's disease therapeutics market is projected to exceed $14.8 billion by 2027. TauRx is positioned to disrupt this market with LMTX®, which targets tau pathology—a promising frontier in neurodegenerative treatment.
TauRx is at the forefront of tau-based research, underpinned by an extensive patent portfolio that safeguards its proprietary therapies and secures its competitive position.
Results from LMTX® clinical trials highlight its potential as a disease-modifying treatment, lowering investment risk relative to other early-stage biotech ventures.
Beyond financial returns, investing in TauRx contributes to a transformative healthcare solution that could dramatically improve the lives of millions.
Notably, applications for regulatory approval are pending in Europe, the US, and Dubai. If approved, LMTX® is expected to launch at a price 50% lower than current treatments, with minimal side effects limited to temporary blue discoloration of urine.
Recognizing the significance of TauRx's innovation, IXS has secured a tranche of TauRx shares through an angel investor. These shares are now available to retail investors via the IXS Launchpad.
Private equity in pioneering biotech companies is often reserved for institutions or high-net-worth individuals due to high entry costs. The IXS Launchpad, powered by blockchain technology, democratizes access by fractionalizing these shares, enabling retail investors to participate with a minimum investment of just $1.
Follow our guide here
Click on this link here
Registration's running from July 24 - July 31, so don't miss out!
Got questions and concerns? Joins us on Telegram